# 1 Pathway-based integration of multi-omics data reveals lipidomics

# alterations validated in an Alzheimer's Disease mouse model and risk loci carriers

- 4
- 5 Monica Emili Garcia-Segura <sup>1,2</sup>, Brenan R. Durainayagam <sup>2,3</sup>, Sonia Liggi <sup>2</sup>, Gonçalo Graça<sup>4</sup>,
- 6 Beatriz Jimenez<sup>5</sup>, Abbas Dehghan<sup>3,6,7</sup>, Ioanna Tzoulaki<sup>3, 6,8,9</sup>, Ibrahim Karaman<sup>4,6</sup>, Paul
- 7 Elliott<sup>3,6,7,8</sup> and Julian L. Griffin<sup>2,3,10</sup> \*
- 8
- 9 <sup>1</sup> Department of Brain Sciences, Imperial College London, London, UK.
- 10 <sup>2</sup> Section of Biomolecular Medicine, Department of Metabolism, Digestion and
- 11 Reproduction, Imperial College London, London, UK.
- <sup>3</sup> UK-Dementia Research Institute (UK-DRI) at Imperial College London, London, UK.
- <sup>4</sup> Section of Bioinformatics, Department of Metabolism, Digestion and Reproduction,
- 14 Imperial College London, London, UK.
- 15 5 Section of Bioanalytical Chemistry and the National Phenome Centre, Department of
- 16 Metabolism, Digestion and Reproduction, Imperial College London, London, UK.
- <sup>6</sup> Department of Epidemiology and Biostatistics, Imperial College London, London, UK.
- <sup>7</sup> MRC Centre for Environment and Health, Imperial College London, London, UK.
- 19<sup>8</sup> National Institute for Health Research Imperial Biomedical Research Centre, Imperial
- 20 College London, UK.
- <sup>9</sup> Department of Hygiene and Epidemiology, University of Ioannina Medical School,
- 22 University Campus Road 455 00, Ioannina, Greece.
- <sup>10</sup> Department of Biochemistry and Cambridge Systems Biology Centre, University of
- 24 Cambridge, Cambridge, UK.
- 25

### 26 Correspondence

- 27 Julian L. Griffin, Biomolecular Medicine, Division of Systems Medicine, Department of
- 28 Metabolism, Digestion and Reproduction, Imperial College London, London, United
- 29 Kingdom. Email: julian.griffin@imperial.ac.uk; Tel.: +44-(0)20-7594-3220

# 3031 Abstract

- 32 Alzheimer's Disease (AD) is a highly prevalent neurodegenerative disorder. Despite
- 33 increasing evidence of important metabolic dysregulation in AD, the underlying metabolic
- 34 changes that may impact amyloid plaque formation are not understood, particularly for late
- 35 onset AD. This study analyzed genome-wide association studies (GWAS), transcriptomics
- 36 and proteomics data obtained from several data repositories to obtain differentially expressed
- 37 (DE) multi-omics elements in mouse models of AD. We characterized the metabolic
- 38 modulation in these datasets using gene ontology, and transcription factor, pathway and cell-
- 39 type enrichment analysis. A predicted lipid signature was extracted from genome-scale
- 40 metabolic networks (GSMN) and subsequently validated in a lipidomic dataset derived from
- 41 cortical tissue of ABCA7-null mice, a mouse model of one of the genes associated with late
- 42 onset AD. Moreover, a metabolome-wide association study (MWAS) was performed to
- 43 further characterize the association between dysregulated lipid metabolism in human blood
- 44 serum and AD.
- 45 We found 203 DE transcripts, 164 DE proteins and 58 DE GWAS-derived mouse orthologs
- 46 associated with significantly enriched metabolic biological processes. Lipid and bioenergetics
- 47 metabolic pathways were significantly over-represented across the AD multi-omics datasets.
- 48 Microglia and astrocytes were significantly enriched in the lipid-predominant AD-metabolic
- 49 twonscriptoman Worshow restracted respective chilipidy signature that or was well idented under robustly ce.

- 50 modelled class separation in the ABCA7 mice cortical lipidome, with 11 of these lipid
- 51 species exhibiting statistically significant modulations. MWAS revealed 298 AD single
- 52 nucleotide polymorphisms (SNP)-metabolite associations, of which 70% corresponded to
- 53 lipid classes.
- 54 These results support the importance of lipid metabolism dysregulation in AD and highlight
- 55 the suitability of mapping AD multi-omics data into GSMNs to identify metabolic alterations.
- 56
- 57
- 58

### 59 Key words

- 60 Alzheimer's Disease; ATP-binding-cassette subfamily-A member-7 gene (ABCA7);
- 61 lipidomics; multi-omics; metabolome-wide association study (MWAS); pathway-based
- 62 integration.63

### 64 Abbreviations

65 Airwave, Airwave Health Monitoring Study; AD, Alzheimer's Disease; Aβ, amyloid-beta;

- 66 APP, amyloid-precursor protein; ABCA7, ATP-binding-cassette subfamily-A member-7
- 67 gene; APOE, apolipoprotein epsilon; ChEA3, ChIP-X enrichment analysis 3; DAVID,
- database for annotation, visualization and integrated discovery; DE, differentially expressed;
- 69 EWCE, expression weighted cell-type enrichment; FDR, false discovery rate; FC, fold
- change; GEO, gene expression omnibus; GRCh37, genome reference consortium-human
- <sup>71</sup> build-37, GSMN, genome-scale metabolic networks; GWAS, genome-wide association
- studies; IGAP, international genomics of Alzheimer's cohorts; iTRAQ, isobaric tag for
- relative and absolute quantification; KO, knock-out; MAGMA, multi-marker analysis of
   genomic annotation; MWAS, metabolome-wide association study; NMR, nuclear magnetic
- genomic annotation; MWAS, metabolome-wide association study; NMR, nuclear magnetic
   resonance; OPLS-DA, orthogonal projections to latent structures-discriminant analysis; PQN,
- resonance; OPLS-DA, orthogonal projections to latent structures-discriminant analysis; PQN,
   probabilistic quotient normalization; PRIDE, protein identification database; RP-UPLC-MS,
- reverse-phase ultraperformance liquid chromatography-mass spectrometry; RS, Rotterdam
- study; SAM, significance analysis of microarray; SNPs, single nucleotide polymorphisms;
- 78 study, SAM, significance analysis of incroarray, SM s, single increating polymorphisms, 79 S.D.f.M, standard deviation from the bootstrapped mean; SREBP2, sterol regulatory element
- 80 binding protein 2; TF, transcription factor; TREM2, triggering receptor expressed on myeloid
- 81 cells-2; UPLC-MS, ultraperformance liquid chromatography-mass spectrometry; VIP,
- 82 variable influence of projection; WT, wild-type;
- 83 84

# 100101 **1 Introduction**

### 102

103 Alzheimer's Disease (AD) is a neurodegenerative disorder prevalent in later life 104 characterized by amyloid deposition, hyperphosphorylated tau aggregation into 105 neurofibrillary tangles and a sustained neuroinflammatory response (DeTure & Dickson 2019). With the proportion of the population over 65 years of age increasing annually, a 106 mechanistic understanding of the disease is urgently needed (Xie et al. 2020). There are 107 108 several emerging lines of evidence highlighting the importance of metabolic dysfunctions in 109 AD. Impaired glycolysis and bioenergetics shifts towards fatty-acid and amino-acid 110 metabolism seem to indicate that mitochondrial dysfunction or substrate switch play a role in 111 AD pathogenesis (Perez Ortiz & Swerdlow 2019). Cholesterol metabolism can also exert lipotoxic effects in the AD brain via ceramide production modulation (Cutler et al. 2004). 112 113 Furthermore, there are several genes linked to AD onset and progression that are also related to brain lipid metabolism. The apolipoprotein epsilon4 (APOE4) allele, the strongest risk 114 115 factor for AD development, is known to cause significant disruptions in brain lipid homeostasis in both human carriers and transgenic animals (Fernandez et al. 2019). 116 Similarly, triggering receptor expressed on myeloid cells-2 (TREM2), another gene strongly 117 118 associated with AD, actively undergoes lipid-sensing and consequently induces changes in the microglia lipidome (Nugent et al. 2020). Finally, loss-of-function variant of the ATP-119 120 binding-casette, subfamily-A, member-7 gene (ABCA7) has been strongly associated with 121 late-onset AD (De Roeck et al. 2019). ABCA7 has been implicated in AD pathology through 122 amyloid-precursor protein (APP) endocytosis, impaired amyloid-beta (A $\beta$ ) clearance and,

- 123 although not fully elucidated, lipid metabolism dysregulation via sterol regulatory element
- 124 binding protein 2 (SREBP2) (Aikawa *et al.* 2018).
- 125

126 Despite all the accumulating evidence, mechanistic explanations of AD have mostly been 127 centered around amyloid or tau-centric hypotheses, and therefore much remains to be

128 understood regarding the underlying metabolic processes (Johnson *et al.* 2020).

- 129 Multi-omics approaches have the potential to overcome the limitations of the current
- 130 knowledge in this field. These approaches can provide a comprehensive view of a particular
- 131 pathophysiological state by interrogating molecular changes across several levels of
- 132 biological functions (Canzler *et al.* 2020). A promising methodological approach relevant to
- the study of metabolites is genome scale metabolic networks (GSMN), which uses genomics
- and transcriptomics data to predict metabolic pathway modulations (Pinu *et al.* 2019). GSMN
- also allow for the interpretation of multi-omics data via metabolic subnetwork curation, thus
- 136 providing an attractive metabolic framework which can be effectively validated using
- 137 metabolomics and lipidomics data (Frainay & Jourdan 2017).
- 138


139 The aim of this study was to validate the presence of metabolic perturbations in AD using 140 multi-omics pathway-based integration and extraction of metabolic subnetworks from open 141 source data (Figure 1). We found consistent perturbations of lipid and energy metabolism

- 141 source data (Figure 1). We found consistent perturbations of lipid and energy inetaboli 142 across three AD multi-omics datasets compiled from previous studies, from which we
- extracted 133 lipid species predicted to be dysregulated in AD which we then validated in an

144 ABCA7 knock-out (KO) mouse dataset acquired with ultraperformance liquid

- 145 chromatography-mass spectrometry (UPLC-MS). The importance of this association was
- 146 explored further by performing a metabolome-wide association study (MWAS) of the blood
- 147 plasma metabolome for AD risk loci carriers in two human cohorts using <sup>1</sup>H NMR
- 148 spectroscopy.
- 149

- 150 This study also highlights the suitability of interpreting multi-omics data in the context of
- 151 GSMNs, as the predicted lipid terms and species were not only found in the cortical ABCA7
- 152 lipidome, but its associated multivariate model robustly separated ABCA7 mice from their
- 153 wild-type (WT) litter-mates.
- 154
- 155
- 156



157 158

### 159 Figure 1. Schematic representation of the experimental design implemented in this

- 160 **study.** Abbreviations: GEO = gene expression omnibus database, PRIDE = protein
- 161 identification database, AD = Alzheimer's Disease, ABCA7 KO = ATP-binding-cassette, 162 subfamily A member 7 gene knock out
- subfamily A, member 7 gene knock-out.
- 163
- 164 165
- 166
- 167

# 168 **2 Materials and Methods**

- 169
- 170 2.1 Data collection of AD mouse brain transcriptomics and proteomics data

The gene expression omnibus (GEO) repository (https://www.ncbi.nlm.nih.gov/geo/) 171 (Clough & Barrett 2016) was queried on 15/06/20 for gene expression studies using 172 "Alzheimer's Disease" as our search term. The following criteria were employed for dataset 173 174 selection: *Mus musculus* organism, expression profiling by array as study-type, tissue as attribute, brain tissue expression compared to WTs and a minimum of 3 animals per 175 176 condition. This search yielded 11 datasets (GSE25926, GSE53480, GSE60460, GSE77574, 177 GSE77373, GSE109055, GSE111737, GSE113141, GSE141509 and GSE74441) from 9 178 studies (Aydin et al. 2011; Polito et al. 2014; Hamilton et al. 2015; Marsh et al. 2016; Wang 179 et al. 2017; Faivre et al. 2018; Hou et al. 2018; Fang et al. 2019; Preuss et al. 2020). 180 The proteomics identifications (PRIDE) repository (Jones et al. 2006) was queried on 01/07/20 for proteomics studies applying the following filters: Alzheimer's Disease as 181 182 disease, brain as organism-part and Mus musculus as organism. Datasets comparing the AD 183 proteome against WTs, with minimum 3 animals per condition and with deposited proteinGroups.txt files were included. This search yielded 4 datasets (PXD007795, 184 PXD011068, PXD012238, and PXD007813) from 4 publications (Palomino-Alonso et al. 185 2017; Hamezah et al. 2019; Kim et al. 2019; Lachen-Montes et al. 2019). However, 186 187 differences in protein expression failed to reach statistical significance after controlling for 188 the false discovery rate (FDR) in two studies (Palomino-Alonso et al. 2017; Hamezah et al. 2019), and thus their corresponding datasets were excluded. A description of all included 189 190 datasets can be found in Table 1. 191

**Table 1**. Characteristics of the transcriptomics and proteomics datasets included in this study

Brain region	GEO/PRIDE accession number	AD animal model	Age	Sample size	ize Platform	
Transcriptomics						
Frontal cortex	GSE113141	APP/PS1	9-10 months	AD (n=6)	Agilent-074809 SurePrint	
				WT (n=6)	G3 Mouse GE v2 8x60K Microarray	
	GSE109055	3xTgAD	22-24	AD (n=4)	Agilent-028005 SurePrint	
			months	WT(n=4)	G3 Mouse GE 8x60K Microarray	
	GSE77373	5xFAD	5 months	AD (n=3) WT(n=3)	Affymetrix Mouse Gene 1.0 ST Array	
	GSE74441	APP/PS1	Not	AD (n=6)	Illumina MouseRef-8 v2.0	
			disclosed	WT (n=6)	expression beadchip	
	GSE25926	APP-KI	24-28	AD (n=3)	Affymetrix Mouse	
			months	WT(n=3)	Genome 430 2.0 Array	
Hippocampus	GSE111737	APP/PS1	8 months	AD (n=6)	Agilent-074809 SurePrint	
				WT (n=6)	G3 Mouse GE v2 8x60K Microarray	
	GSE109055	3xTgAD	22-24	AD (n=4)	Agilent-028005 SurePrint	
			months	WT(n=4)	G3 Mouse GE 8x60K	
					Microarray	
	GSE53480	Tg4510	4 months	AD (n=4)	Affymetrix Mouse	
				WT(n=4)	Genome 430 2.0 Array	
Subventricular zone	GSE60460	3xTgAD	7 months	AD (n=4)	Agilent-028005 SurePrint	
				WT(n=4)	G3 Mouse GE 8x60K Microarray	
Half-brain	GSE141509	5xFAD	6 months	AD (n=6)	NanoString nCounter®	
				WT (n=6)	Mouse AD panel	

Whole brain	GSE77574	5xFAD	6-7 months	AD (n=4) WT(n=4)	Affymetrix Mouse Transcriptome Array 1.0	
Proteomics						
Hippocampus	PXD012238	5xFAD	10 months	AD (n=6)	Orbitrap MS/MS- Q-	
				WT (n=6)	Exactive	
Olfactory bulb	PXD007813	Tg2576	6 months	AD (n=3)	iTRAQ-LC MS/MS	
				WT(n=3)	with Triple TOF MS 5600	

193

2.2 Differential expression (DE) analysis of AD mouse transcriptomics and proteomics data 194

195 Processed transcriptomics datasets were retrieved from GEO using the GEOquery

Bioconductor-based package (version 2.54.1) (Davis & Meltzer 2007) in the R environment, 196

197 version 3.6.2 (https://www.R-project.org). Datasets were log-2 transformed and graphically inspected to verify appropriate data normalization; probes that were not mapped to any genes,

198 mapped to more than one gene and probes with missing values (N/As) were filtered out. 199

200 Differential expression analysis was performed using significance analysis of microarray

201 (SAM) with samr package (version 3.0) (Tusher et al. 2001) within the R environment. SAM

can control for the total number of false positives through both gene specific t-tests and a 202

maximum local tolerable FDR (Tusher et al. 2001). Upon 200 permutation-based SAM 203

analysis, multiple testing correction was applied by adjusting the total false positives to 3% 204 and the local FDR for 90<sup>th</sup> percentile of DE genes to 5% in every dataset. 205

206

207 Proteomics datasets were analyzed using Perseus (version 1.6.5) (Tyanova et al. 2016).

208 Initially, proteins only identified by reverse-decoy, site or known contaminants were

excluded, as well as proteins with 2/3 of replicates per group reporting N/As. Protein 209

210 intensities were then log-2 transformed and remaining N/As were replaced using normal

211 distribution values, as most proteomics studies assume N/As are indicative of low-expression

212 proteins (Tyanova et al. 2016). DE proteins were determined using a two-tailed Student's t-

213 test with a 200 FDR permutation-based method and a 0.050 p-value cut-off (Tusher et al.

214 2001). In isobaric tag for relative and absolute quantification (iTRAQ) experiments, an

additional fold change (FC) 1.17-0.83 cut-off was introduced to determine DE proteins. 215 216 iTRAQ experiments are prone to interference/ratio distortion (Pappireddi et al. 2019), and

217 thus a combination of p-value, FDR and FC cut-off is the most suitable approach to detect biological variability (Oberg & Mahoney 2012).

218

219 220 2.3 AD genome-wide association studies (GWAS) gene-based analysis and mouse ortholog

221 determination

222 AD GWAS summary statistics were obtained from a meta-analysis of the UK-Biobank and

International Genomics of Alzheimer's Project (IGAP) cohorts, which evaluated GWAS with 223

224 AD by-proxy in 388364 individuals across both cohorts (Marioni et al. 2018). Summary

225 statistics (ID: GCST005922) were retrieved from the NHGRI-EBI GWAS-Catalog

226 (https://www.ebi.ac.uk/gwas/) (Buniello et al. 2019) on 07/07/2020.

227

228 Gene-based analysis was performed with multi-marker analysis of genomic annotation

229 (MAGMA, version 1.07bb) (de Leeuw et al. 2015), using gene locations from the genome

reference consortium-human build-37 (GRCh37, NCBI) and a reference panel of European 230

231 ancestry from the 1000 genomes project phase-3 (Auton et al. 2015). MAGMA provides a

232 combined p-statistic of genes significantly associated with single nucleotide polymorphisms

233 (SNPs) (de Leeuw et al. 2015); we used a combined 0.050 p-value as a significance cut-off.

234 Significant genes were imported into Ensembl–Biomart on 20/07/2020 (version GrCh37.13;

235 https://grch37.ensembl.org/biomart/martview) to determine high confidence mouse orthologs

- 236 (Zerbino et al. 2018). Upon excluding genes associated with either several or no mouse
- 237 orthologs, only those exhibiting one-to-one bidirectional orthology with 60% protein
- sequence similarity across both species were considered high-quality mouse orthologs 238
- 239 (Mancuso et al. 2019).
- 240
- 241 2.4 Gene ontology (GO) analysis and AD-metabolic multi-omics extraction
- 242 DE transcripts, proteins and GWAS-orthologs were initially mapped onto the BioCyc Mus
- 243 musculus GSMN (Caspi et al. 2016) using MetExplore, which provides a framework for
- 244 metabolic subnetwork extraction(Cottret et al. 2018). DE transcripts, protein-coding and
- 245 GWAS-orthologs genes that were not mapped onto the GSMN were removed; the resulting
- omics lists are referred to as "all-mapped" data throughout this study. Significantly enriched 246
- 247 functional terms were identified in all-mapped AD omics datasets using the database for 248 annotation, visualization and integrated discovery (DAVID, version 6.8)
- 249 (https://david.neifcrf.gov/) (Dennis et al. 2003). and the Mus musculus genome as
- background. GO analysis was performed using a hypergeometric test with an EASE score of 250
- 251 0.1 and a count threshold of 2. Terms with both raw p-value and Benjamini-Hochberg (B-H)
- 252 FDR-adjusted p-value (a) below 0.050 were considered statistically significant. Metabolism-
- 253 related transcripts, proteins and GWAS-orthologs were manually extracted from significantly 254 enriched biological processes (BP).
- 255
- 256 2.5 Transcription Factor (TF) enrichment analysis
- TF enrichment analysis was performed on all-mapped AD genes and proteins, as well as their 257 258 metabolic counterparts, using ChIP-X enrichment analysis 3 (ChEA3)
- 259 (https://maayanlab.cloud/chea3/). ChEA3 performs enrichment analysis based on TF's target
- 260 genes coverage using the Fishers exact test and B-H adjusted p-value at 0.050 threshold
- 261 (Keenan et al. 2019). The ENCODE library was chosen as our reference set, as it
- incorporates TF-target associations from human and mouse data (Davis et al. 2018). 262
- Significantly enriched TF were manually cross-referenced with the mouse transcription factor 263 264 atlas to verify its mouse tissue expression (Zhou et al. 2017).
- 265

266 2.6 Pathway enrichment analysis of AD-metabolic multi-omics data

- AD metabolic transcripts, proteins and GWAS-orthologs lists were mapped onto the BioCyc 267
- Mus musculus GSMN (Caspi et al. 2016) in MetExplore (Cottret et al. 2018). Metabolic 268
- 269 pathway enrichment analysis was performed using hyper-geometric tests with right-tailed
- 270 Fishers exact tests with B-H correction for multiple testing ( $\alpha$ =0.050).
- 271
- 272 2.7 Expression-weighted cell-type enrichment (EWCE) of AD-metabolic multi-omics data
- 273 EWCE was conducted on AD-metabolic transcriptomics, proteomics and GWAS-orthologs
- 274 datasets using the EWCE package in R (version 0.99.2)(Skene & Grant 2016). EWCE
- 275 computes an enrichment p-value that describes the probability of an input gene list having a
- 276 meaningful expression within a specific cell-type upon 10000 random permutations (Skene &
- 277 Grant 2016). A cortical and hippocampal single-cell RNA-sequencing dataset with large
- 278 coverage was used as background (Zeisel et al. 2015); B-H adjusted p-values were calculated
- using the R base package. A conditional EWCE analysis was also performed on the 279
- 280 combined AD-metabolic multi-omics dataset to probe the relationships between enriched
- 281 cell-types, using an approach originally developed for GWAS data analysis (Skene et al. 2018).
- 282
- 283
- 2.8 Metabolic subnetwork extraction 284

To ultimately validate lipid alterations highlighted during pathway enrichment analysis, a
metabolic subnetwork containing all lipid terms or species in significantly enriched lipid

287 pathways was mined across the AD-metabolic transcriptome and proteome using MetExplore

- (Cottret *et al.* 2018). After excluding non-lipid metabolites, a combined predicted lipid
   signature across the AD multi-omics datasets was created, which was visualized using
- 200 MetExploreViz (Chazalviel *et al.* 2018). Lipid identifiers were then retrieved from
- 291 LIPIDMAPS (Fahy et al. 2009).
- 292

# 293 2.9 Cortical ABCA7-KO lipidomics dataset

294 We also employed a lipidomics dataset of cortical extracts of 7 WT and 7 ABCA7-KO 11months old mice, with 3 females and 4 males per group, as described previously (Aikawa et 295 296 al. 2018). Lipidomic extraction was performed on ~50mg cortex tissue using a modified 297 Folch extraction (Su et al. 2019). Global lipidomic profiling of the cortical extracts and 3 pooled samples was acquired using a reverse-phase ultraperformance liquid chromatography-298 299 mass spectrometry (RP-UPLC-MS) on a Synapt Quadruple-Time of Flight mass spectrometer 300 (Waters Corp., Manchester, UK) in positive and negative mode. Details of systems 301 configuration and analytical conditions have been previously reported (Andreas et al. 2020). 302 Data processing was performed with KniMet (Liggi et al. 2018). Briefly, signals extracted using the R library XCMS (Tautenhahn et al. 2012) were retained if present in at least 50% 303 304 of the pooled samples with a Coefficient of Variation <= 20. Remaining signals were subjected to imputation of N/As using K-Nearest Neighbour (KNN), probabilistic quotient 305 306 normalization (PON) based on pooled samples, and annotation using LIPID MAPS 307 (https://lipidmaps.org/; (Fahy et al. 2009)), retention time matching to standards and fragmentation data.

308 309

# 310 2.10 Multivariate statistical analysis

Multivariate statistical analysis was performed on both positive and negative mode for the
original ABCA7-KO and validated lipid signature subsets using P-SIMCA (Umetrics,
Sweden) following log-transformation of intensities and Pareto-scaling. Orthogonal
projections to latent structures-discriminant analysis (OPLS-DA) models, which allow to
evaluate the impact of group membership by separating the variance attributed or orthogonal
to class membership into components, were created for both original datasets and validated
subset in positive and negative ion mode (Griffin *et al.* 2020). Lipids in the validated subset

- 318 in positive and negative mode with variable influence of projection (VIP) > 1 were retained
- for univariate analysis, as OPLS-DA generated VIP > 1 indicate specific variables with important contributions to the model (Liu *et al.* 2020). The suitability of the models were
- assessed through inspection of their  $R^2(cum)X$  and  $Q^2$  values, which respectively represent
- the percentage of model-captured variation and predictive capability (Liu *et al.* 2020).
- 323 Models were further validated with a 100 permutation-based test, in which the correlation
- 324 coefficient for the permuted class-membership variable is plotted against the  $R^2(cum)X$  and 325  $O^2(cum)$  (Murgia *et al.* 2017).
- 326
- 327 2.11 Univariate statistical analysis

328 AD multi-omics lipid species that had an associated VIP score above 1 in the original

- 329 ABCA7 KO lipidomics dataset underwent univariate statistical analysis using GraphPad
- 330 Prism (p<0.05). Negative-mode acquired lipids underwent both a Student t-test and Mann-
- 331 Whitney non-parametric test comparing genotype (p<0.05), whereas positive-mode acquired
- 332 lipids were analyzed using One-way ANOVA comparing genotype and sex correcting for
- 333 multiple testing using B-H method ( $\alpha < 0.05$ ).
- 334

# 2.12 Metabolome-wide association study (MWAS) of the blood plasma metabolome for AD risk loci carriers

337 We performed an MWAS using nuclear magnetic resonance (NMR) spectra of blood from 338 3258 individuals from the Airwave Health Monitoring Study (Airwave) and the Rotterdam Study (RS) prospective cohorts (Elliott et al. 2014; Ikram et al. 2020). Ethical approval for 339 340 access to the Airwave cohort was granted following application to the access committee via 341 the Dementia Platform UK (https://portal.dementiasplatform.uk/). Access to the RS cohort 342 was granted following access to the Management Committee and conducted under approval 343 from the Ministry of Health, Welfare and Sport of the Netherlands. Blood samples were 344 heparin plasma for Airwave and serum for RS. Average age at enrolment in 2004 was 40.9 years for men and 38.5 years for women in the Airwave cohort; the RS cohort mean age of 345 346 recruitment was 55 for both genders in 1990 (Elliott et al. 2014; Ikram et al. 2020) 347 Sample preparation and metabolic profiling in these cohorts have been extensively described (Tzoulaki et al. 2019; Robinson et al. 2020). Briefly, <sup>1</sup>H NMR solvent suppression pulse and 348 349 T2-Carr-Purcell-Meiboom-Gill (CPMG) spectra were acquired per sample (Dona A.C. et al. 2014) and additionally lipid quantification was applied on the <sup>1</sup>H NMR solvent suppression 350 351 pulse spectra using a commercial package (Jiménez et al. 2018). Resonances associated with 352 both protons attached to the fatty acid and the head group (largely choline and glycerol) along

- with protons from cholesterol and cholesterol esters were classified as belonging to the lipidclass.
- 355

356 MWAS was performed using 47 unique genetic loci based on three recent GWAS meta-

analysis on AD to identify AD risk loci carriers (Lambert *et al.* 2013; Jansen *et al.* 2019;

Kunkle *et al.* 2019). These studies evaluated genome-wide associations with late-onset AD
(LOAD) in individuals across the IGAP and UK-Biobank cohorts.

360

### 361 2.13 MWAS association statistics

362 We carried out a linear regression to calculate the effect estimates of each SNP with all

metabolomic features (23,571 data points for original NMR spectra and 105 features for the fitted lipid data) with adjustment for age, sex, and cohort. Prior to the analysis, each cohort data was residualised using 10 principal components from genome-wide scans to adjust for population stratification. To account for multiple testing, we used a permutation-based method to estimate the Metabolome Wide Significance Level (MWSL) to consider the high degree of correlation in metabolomics datasets (Chadeau-Hyam M *et al.* 2010; Castagné R *et al.* 2017). A P-value threshold giving a 5% Family-Wise Error Rate was computed for each

- 370 SNP in each data platform.
- 371

### 372 **3 Results**

#### 373

374 3.1 DE analysis of mapped AD mouse transcriptomics and proteomics data

375 DE transcripts and proteins in the AD mouse brain with potential metabolic functions were extracted from the GEO and PRIDE repositories, respectively. Microarray expression profiles 376 from 11 datasets were obtained from 5 distinct brain regions (frontal cortex, hippocampus, 377 sub-ventricular zone, brain hemisphere and whole-brain) and 5 AD mouse models (APP/PS1, 378 5xFAD, 3xTgAD, APP-KI and Tg4510; Table 1). SAM revealed 2884 DE genes with a 90<sup>th</sup> 379 percentile FDR below 5%. Of these, 594 were accurately mapped onto the GSMN, which 380 were used to generate the all-mapped AD transcriptomics dataset. Furthermore, proteomics 381 382 datasets from the hippocampus and olfactory bulb of 5xFAD and Tg2576 mice, respectively, 383 were also obtained (Table 1). Permutation-based analysis revealed 1537 DE proteins (FDR p < 0.050), of which 392 were mapped onto the GSMN and therefore constituted the all-384 385 mapped AD proteomics dataset. DE proteins from two additional studies (Palomino-Alonso et al. 2017; Hamezah et al. 2019) failed to reach statistical significance upon FDR correction 386 and thus these datasets were removed from further analysis. 387

388

389 3.2 Mapped high-quality mouse orthologs identification from gene-based AD GWAS analysis High-confidence mouse orthologs of significantly associated genes in human AD GWAS 390 391 studies were also identified to gain a more comprehensive view of metabolic perturbations in 392 AD. Gene-based analysis with MAGMA (de Leeuw et al. 2015) using summary statistics 393 from 388364 individuals in the UK-Biobank and IGAP cohorts (Marioni et al. 2018) revealed 394 18178 gene-level associations with human AD SNPs, of which 1664 were considered 395 significant (combined p-value < 0.05). After applying high-quality mouse orthology criteria 396 (Mancuso et al. 2019), 1356 high-quality orthologs of AD SNPs-associated human genes 397 were identified. The all-mapped AD GWAS-orthologs dataset was generated by accurately

- 398 mapping 258 GWAS-orthologs onto the GSMN.
- 399


400 3.3 Differential GO and TF enrichment analysis across AD multi-omics datasets

Potential TF and GO enrichment were investigated across the AD multi-omics datasets. More
than 25% of mapped AD protein-coding genes were also found in the AD transcriptomics
dataset (Figure 2A). In terms of up-stream regulation, 67 TF were significantly enriched in
the all-mapped AD proteome, whereas only 17 TF were enriched in the all-mapped AD
transcriptome (Table S1). Despite these differences, *CCCTC-binding factor (CTCF)*, *TAL*BHLH transcription factor 1 (TAL1), MYC associated factor X (MAX) and basic helix-loop-

- 407 *helix family member E40 (BHLHE40)* were among the top10 potential enriched TFs across
- 408 both datasets (FDR p<0.050, Figure 2B, Table S1).
- 409


410 GO analysis revealed shared functional terms across the three datasets (Figure 2C-D).

- 411 Oxidation-reduction, lipid and fatty-acid metabolic processes were enriched in all-mapped
- 412 AD transcriptomics and proteomics (FDR p<0.050, **Figure 2C**). Six additional lipid-related
- 413 BP terms were over-represented in all-mapped AD transcriptomics data, whereas the TCA
- 414 cycle was only enriched in the AD proteome (FDR p<0.050, Figure 2C). Transferase,
- 415 catalytic, ATP binding, kinase activity, nucleotide binding and serine/threonine-kinase
- 416 activity were among the top10 over-represented terms across all-mapped AD multi-omics
- 417 datasets (FDR p<0.050, **Figure 2D**). Cytosol and mitochondria were the cellular
- 418 compartment (CC) terms most over-represented in the all-mapped AD transcriptome and
- 419 proteome respectively; membrane was the only significant CC term in the AD GWAS-
- 420 orthologs dataset (Table S2).
- 421





422



of three AD multi-omics datasets. "Ac" refers to molecular function activity. TF ratio refers
to the number of mapped input genes in relation to the total TF's target genes. -log10(FDR)

434 refers to the inverse, log-transformed FDR-adjusted enrichment p-value. Gene ratio refers to

the number of mapped input genes in relation to all Gene Ontology (GO) term-associated
genes. The entire list of over-represented TF and GO terms can be found in Table S1 and S2,


437 respectively.


#### 439

# 440 *3.4 Lipid-related metabolic pathways and regulators are enriched across AD-metabolic* 441 *multi-omics datasets*

442 Given the elevated number of metabolic BP significantly enriched across the three multiomics datasets, the DE 203 transcripts, 164 proteins and 58 GWAS-orthologs genes mapped 443 to these BP were subjected to further characterization. The largest degree of overlap was 444 445 again found between AD-metabolic transcripts and proteins (Figure 3A). Although there were substantially more enriched TFs in the AD-metabolic proteome (Table S3), lipid-446 447 associated TFs such as *estrogen-related receptor alpha (ESRRa)* and *sterol regulatory* 448 element binding transcription factor 1 (SREBF1) were overrepresented in the AD-metabolic transcriptome and proteome (FDR p<0.050, Figure 3B). Pathway enrichment analysis 449 450 reflected differential metabolic processes across the multi-omics datasets (Figure 3C). 451 Pathways related to cholesterol, phospholipases and fatty-acid metabolism were significantly over-represented in the AD-metabolic transcriptomics dataset, whereas the AD-metabolic 452 proteome was associated with mitochondrial processes such as TCA cycle, glycolysis and 453 NADH electron transfer (FDR p<0.050, Figure 3C). Lipid processes such as CPD-454

- diacylglycerol and phosphatidylglycerol synthesis were also enriched in AD-metabolic
- 456 proteome (**Figure 3C**). Thyroid hormone metabolism was significantly enriched in the
- 457 GWAS-orthologs dataset with 66% pathway coverage (**Table S4**).
- 458





459 460

461 Figure 3. TF and pathway enrichment analysis highlights enrichment of lipid-related

462 metabolic processes in metabolic transcriptomic and proteomic datasets from mouse

463 models of AD. (A) Venn Diagram showing the amount of overlap between AD metabolic

464 multi-omics datasets. (B) Top 10 TFs significantly overrepresented in AD metabolic

transcripts and proteins. (C) Pathway enrichment analysis of the three AD multi-omics
datasets. "bs.", "e.d." and "e.t." refer to biosynthesis, electron donors and electron transfer
processes, respectively. -log10(FDR) refers to the inverse, log-transformed FDR-adjusted
enrichment p-value. TF ratio refers to the number of mapped input genes in relation to the
total TF's target genes. Gene and protein coverage refer to the number of mapped input
elements in relation to all pathway-mapped elements. The entire list of significantly enriched
metabolic TF and pathways can be found in Table S3 and S4.


472

473 *3.5 Astrocytes and microglia are independently enriched in the AD-metabolic transcriptome* 

- 474 To determine whether cell-type enrichment differences across the AD-metabolic multi-omics
- 475 datasets could account for the differential pathway over-representation described previously,
- unconditional EWCE was performed. Significant astrocyte (FDR p-value=0.0000001,
- 477 standard deviation from the bootstrapped mean or S.D.f.M=7.266) and microglia enrichment
- 478 (FDR p-value=0.0000001, S.D.f.M=5.770) was found in the AD-metabolic transcriptomics
- 479 dataset (**Figure 4A**). Oligodendrocyte and astrocyte enrichment in the AD-metabolic
- 480 proteome lost significance upon multiple-testing correction (FDR p-value=0.07 &
- 481 S.D.f.M=2.474 and FDR p-value=0.095 & S.D.f.M=2.049 respectively, Figure 4B).
- 482 Astrocyte enrichment was also similarly lost in the GWAS-orthologs dataset (FDR p-
- 483 value=0.336, S.D.f.M=1.75, **Figure 4C**).
- 484

485 Conditional cell-type enrichment was performed on a combined AD-metabolic multi-omics

- 486 dataset to investigate enrichment relationships. Controlling for microglia did not ablate
- 487 astrocytic enrichment (FDR p-value=0.0000001, S.D.f.M=7.540) and vice-versa (FDR p-
- 488 value=0.0000001, S.D.f.M=4.476), suggesting astrocyte and microglia enrichments were
- 489 independent of each other (Figure 4D). Oligodendrocyte enrichment was however dependent
- 490 on microglia and astrocytes, as significance was lost upon controlling for either of them
- 491 (FDR p-value=0.0389 & S.D.f.M=2.531 and FDR p-value=0.0389 & S.D.f.M= 2.387
- 492 respectively, **Figure 4D**). Cell-type enrichment statistics can be found in **Table S5**.
- 493



494 495

# 496 Figure 4. Cell-type enrichment analysis of individual and combined AD-metabolic

497 multi-omics datasets highlight independent astrocyte and microglia enrichment.

Unconditional cell type enrichment analysis of AD metabolic (A) transcriptomics (B)
proteomics and (C) GWAS-orthologs datasets. (D) Conditional cell-type enrichment analysis
of combined AD multi-omics dataset. "S.S.f.M" indicates standard deviation from the
bootstrapped mean. Asterisk indicates statistical significance upon adjusting for FDR with
the Benjamini-Hochberg (B-H) method (p<0.050).</li>

503

504 3.6 Validation of AD multi-omics lipid signatures in ABCA7 KO mice cortex

Given the number of significantly enriched lipid pathways, the results obtained from the
multi-omics datasets were validated by comparing them to an internally acquired lipidomics
UPLC-MS dataset from cortical extracts of ABCA7-KO and WT mice. To do so, a metabolic
subnetwork containing all the significantly enriched lipid pathways was extracted from the

- generic mouse GSMN (Figure 3C, Table S4). This subnetwork involved 119 genes, 81
  reactions and 107 metabolites. Of these, 73 were lipid species or terms, as some of them
- 510 reactions and 107 metabolites. Of these, 73 were lipid species or terms, as some of them 511 referred to a lipid sub-class, for example a CDP-diacylglycerol, rather than unique species.
- 512 Upon lipid identifier retrieval, those 73 terms were associated with 133 lipid species, which
- 513 generated the AD multi-omics predicted lipid signature.
- 514
- 515 Twenty-eight terms and 60 lipid species from the predicted AD multi-omics lipid signature
- 516 were found and therefore validated in the ABCA7-KO and WT lipidomes. In particular, 40
- 517 lipid species were validated in the negative-mode dataset and 20 species in the positive-mode


- dataset. The original MS data, containing 5025 and 5811 features in positive and negative 518 519 ionization mode, respectively, was hence filtered based on these two subsets of lipid species. OPLS-DA was then performed on both original and filtered datasets to assess the presence of 520 521 any possible separation based on gender and/or genotype, and the potential impact of this 522 feature reduction procedure on the model robustness. 523 524 The OPLS-DA model for the negative-mode validated lipid signature was able to separate 525 ABCA7 and WT samples with an even higher degree of robustness than the original dataset 526  $(Q^2cum=0.74 \text{ and } Q^2cum=0.56, \text{ respectively})$ , which was validated via permutation testing 527 (Table 2, Figure 5A-B). As illustrated by the model's score plot, sample separation was substantially influenced by genotype rather that by variation orthogonal to class membership 528 529 (Figure 5B). 530 Table 2. OPLS-DA model parameters for each original ABCA7 dataset and the validated 531 multi-omics lipid signatures subsets. 532
- 533
- 534

Model	Class	$\mathbf{R}^2 \mathbf{x}$	R <sup>2</sup> y	$Q^2$	100 permutations	100 permutations
	number	(cum)	(cum)	(cum)	R <sup>2</sup> y(cum) intercept	Q <sup>2</sup> (cum)intercept
Original ABCA7-KO negative-	2	0.65	0.90	0.56	(0.0, 0.90)	(0.0, -0.35)
mode						
Validated lipid signature,	2	0.91	1.00	0.74	(0.0, 1.00)	(0.0, -0.37)
negative-mode subset						
Original ABCA7-KO negative-	4	0.80	0.88	0.36	(0.0, 0.83)	(0.0, -0.27)
mode						
Validated lipid signature,	4	0.81	0.77	0.25	(0.0, 0.56)	(0.0, -0.64)
negative-mode subset						
Original ABCA7 KO positive-	2	0.92	0.80	0.56	(0.0, 0.82)	(0.0, -0.44)
mode						
Validated lipid signature,	2	0.94	0.77	0.43	(0.0, 0.57)	(0.0, -0.71)
positive-mode subset						
Original ABCA7 KO positive-	4	0.93	0.85	0.41	(0.0, 0.61)	(0.0, -0.44)
mode						
Validated lipid signature,	4	0.89	0.47	0.20	(0.0, 0.16)	(0.0, -0.31)
positive-mode subset						

535

536 Genotype separation was also captured in the OPLS-DA models for the positive-mode 537 original dataset, although less readily differentiated than its negative-mode counterpart (Table 2). The robustness of the OPLS-DA model assessing genotype separation for the 538 539 positive-mode validated lipid signature was impacted by the presence of an outlier (**Table 2**). A strong genotype-sex interaction influenced sample separation in the original positive-mode 540 cortical dataset (Q<sup>2</sup>cum=0.406, Figure 5C), but not in the negative mode cortical dataset 541 (Q<sup>2</sup>cum=0.36, **Table 2**). Since the AD multi-omics datasets did not consider sex composition, 542 the positive-mode validated lipid signature should not account for genotype-sex interactions 543 either. Indeed, the genotype-sex interaction was not recapitulated in the positive-mode 544

validated signature subset (Q<sup>2</sup>cum=0.20, Table 2, Figure 5D), while the same model for the
negative subset was not calculated due to the lack of statistical power on the correspondent
analysis of the original dataset. Therefore, the validated lipid signature in the negative mode
seemed robustly influenced by ABCA7 genotype.



#### 551

001	
552	Figure 5. OPLS-DA analysis and permutation test of lipidomics analysis of ABCA7-KO
553	cortical samples and validated lipid signature subsets. OPLS-DA score plot and
554	subsequent 100 permutation test of A) Original ABCA7-KO lipidomics dataset in negative
555	mode ( $R^2x$ cum = 0.65, $Q^2$ cum = 0.56, $R^2x$ cum intercept at 0.0, 0.90 and $Q^2$ cum intercept at
556	0.0, -0.35). B) ABCA7 KO lipidomics subset corresponding to the validated lipid signature in
557	negative mode ( $R^2x$ cum = 0.91, $Q^2$ cum = 0.74, $R^2x$ cum intercept at 0.0, 1.00 and $Q^2$ cum
558	intercept at 0.0, -0.37). C) Original ABCA7-KO lipidomics dataset in positive mode (R <sup>2</sup> x
559	cum = 0.93, $Q^2$ cum = 0.41, $R^2$ x cum intercept at 0.0, 0.61 and $Q^2$ cum intercept at 0.0, -0.44).
560	<b>D</b> ) ABCA7-KO lipidomics subset corresponding to the validated lipid signature in positive
561	mode ( $R^2x$ cum = 0.89, $Q^2$ cum = 0.20, $R^2x$ cum intercept at 0.0, 0.16 and $Q^2$ cum intercept at
562	0.0, -0.31).
563	
564	We then inspected the VIP scores of the original ABCA7 datasets to investigate whether the

We then inspected the VIP scores of the original ABCA7 datasets to investigate whether the predicted lipid signature could play a role in driving class separation in relation to the entire ABCA7 lipidome. Out of the 17 predicted lipid species with a VIP score above 1 in the original ABCA7 lipidome (**Table 3**), 11 were significantly modulated, suggesting the AD multi-omics lipid signature was able to successfully predict significant changes in the ABCA7 cortical lipidome.

570

573

571 Table 3. 17 predicted lipid species in the AD multi-omics datasets with a VIP score > 1 in
572 the ABCA7 cortical lipidome.

Predicted lipid species	GSMN's ID	Detected lipids	LIPIDMAPS ID	Ionization mode	VIP score	Statistical test
A fatty aldehyde	Fatty-Aldehydes	$C_{26}H_{52}O$	LMFA06000107	Negative	1.45	0.455
A saturated-Fatty-	Saturated Fatty-acyl	$C_{40}H_{72}N_7O_{18}P_3S$	LMFA07050225	Negative	1.32	0.0530
AcylCoA	CoA					
Lathosterol	CPD-4186	$C_{27}H_{46}O$	LMST01010089	Negative	1.19	0.0070*
A L-1-	L-1-PHOSPHA	$C_{49}H_{85}O_{10}P$	LMGP04010004	Negative	1.14	0.1282
phosphatidyl-	TIDYL-					
glycerol	GLYCEROL					
A Phosphatidyl-	PHOSPHATIDYL	$C_{44}H_{88}NO_8P$	LMGP01010006	Negative	1.13	0.6200
choline	CHOLINE					
Cholesterol	CHOLESTEROL	$C_{27}H_{46}O$	LMST01010001	Negative	1.11	0.0262*
A fatty acid	Fatty-Acids	$C_{22}H_{37}NO_2$	LMFA08040001	Negative	1.04	0.5350
		$C_{18}H_{30}O_2$	LMFA01030152	Positive	1.09	0.0268\$
A 1-acyl glycero-	1-Acylglycero-	$C_{28}H_{50}NO_7P$	LMGP01050140	Negative &	1.03	0.5530
phosphocholines	Phosphocholines			Positive		
		$C_{26}H_{52}NO_7P$	LMGP01050138	Positive	1.17	0.0342\$
A CDP-	CDPDIACYL-	$C_{48}H_{85}N_3O_{15}P_2$	LMGP13010004	Negative	1.09	0.0273*
diacyl-glycerol	GLYCEROL					
A diacylglycerol	DIACYL	$C_{35}H_{68}O_5$	LMGL02010001	Positive	1.50	0.0291\$
	GLYCEROL					
		$C_{39}H_{76}O_5$	LMGL02010002	Positive	1.18	0.0227\$

4α-hydroxymethyl-	CPD-4575	$C_{29}H_{48}O_2$	LMST01010232	Positive	1.44	0.0291\$
4β-methyl-5α-						
cholesta-8,24-dien-						
3β-01						
Ubiquinol-8	CPD-9956	$C_{49}H_{74}O_4$	LMPR02010005	Positive	1.07	0.0247\$
An acyl-sn-	ACYL-SN-	$C_{21}H_{43}O_7P$	LMGP10050005	Positive	1.07	0.0295\$
Glycerol-	GLYCEROL-3P					
3phosphate						
7-dehydro-	CPD-4187	$C_{27}H_{44}O$	LMST01010069	Positive	1.04	0.0427\$
cholesterol						

574

575 Predicted lipid signature was derived from an extracted metabolic subnetwork containing all 576 significantly enriched lipid metabolic pathways in the AD transcriptomics and proteomics datasets, which contained 73 lipid terms. If species in the predicted lipid signature referred to a lipid class, all of 577 578 the detected compounds belonging to that lipid class were considered for the analysis. This approach 579 yielded 133 unique lipid species, which were mapped to 60 and 20 lipids detected in negative and positive ion mode, respectively. Of these predicted lipid species, 17 had a VIP score > 1 in the OPLS-580 581 DA models for the original ABCA7 datasets. \*References to p <0.050 significance upon unpaired t-test 582 and Mann Whitney non-parametric testing on intensity differences between ABCA7 and WT mice in 583 the original negative mode ABCA7 dataset. <sup>\$</sup> refers to significance upon One-way ANOVA using B-H 584 correction for multiple testing on differences between ABCA7-males and ABCA7-females, WT-585 females or WT-males in the original positive mode ABCA7 dataset.

586

587 *3.7 Validation of lipid-AD risk loci associations in the Airwave and RS cohorts.* 

Lastly, we performed a MWAS using <sup>1</sup>H NMR spectra of human blood serum from 3258 individuals from the Airwave and RS cohorts (Elliott *et al.* 2014; Ikram *et al.* 2020). As these cohorts consist of predominantly healthy individuals, we used 47 known AD risk loci to identify AD risk carriers (Lambert *et al.* 2013; Jansen *et al.* 2019; Kunkle *et al.* 2019).


592

After performing MWAS, we detected 298 SNP-metabolite associations from the three NMR pulse sequences, out of which 107 in the lipoprotein, 13 in the CPMG, and 178 in the solvent suppression pulse sequence spectra datasets. Association with *APOE* was found for 83% of these, reflecting the importance of this gene in regulating components of the blood metabolome (**Figure 6a**).

598

599 To examine the associations further we classified the detected metabolites according to their 600 chemical characteristics and biological role into lipids, amino acids, carbohydrates, glycolysis 601 intermediates, TCA cycle intermediates, ketone bodies and other metabolites. Lipids included 602 resonances that were associated with both protons attached to the fatty acid and the head 603 group (largely choline and glycerol) along with protons from cholesterol and cholesterol 604 esters. The dominant class was represented by lipids, comprising over 70% of the 605 associations (**Figure 6b**).

606



#### 611 Figure 6: Metabolome-wide association study of the blood metabolome for AD risk

612 genes in the Airwave and RS cohorts. A) Proportion of AD risk genes significantly

associated with fluctuating metabolite levels detected in the blood samples of individuals in

the Airwave and RS cohorts. MWSL was set to 0.05 upon 10,000 permutations to control for

FWER. **B**) Proportion of metabolite classes associated with AD risk loci in the Airwave and

616 RS cohorts. MWSL was set to 0.05 upon 10,000 permutations to control for FWER.

### 642

### 643 **4 Discussion**

644

645 The main aim of this study was to validate the presence of metabolic perturbations in AD 646 using multi-omics pathway-based integration and metabolic-subnetwork extraction. We 647 hypothesized that metabolic alterations detected at multiple omics levels could predict a 648 robust metabolic signature in the AD metabolome. If validated, these results would provide a 649 comprehensive perspective on AD metabolism while supporting the use of GSMNs to 650 identify consistent metabolic alterations in AD.

651

652 GO analysis of AD transcriptomics, proteomics and GWAS-orthologs data revealed numerous enriched metabolic BP. Although the initial mapping of DE transcripts, proteins 653 and GWAS-orthologs certainly removed elements with no metabolic roles, this step did not 654 655 disproportionately influence metabolic BP term over-representation per se, as only 3 out of 11 BP in mapped GWAS-orthologs were metabolic. Lipid and fatty-acid BP enrichment was 656 found across the AD all-mapped transcriptome and proteome. This observation was further 657 658 supported by TAL1, MAX and BHLHE40 over-representation in both datasets. TAL1 modulates lipid metabolism in the context of cell membrane integrity (Kassouf et al. 2010), 659

660 *MAX-MYC* interaction strongly dysregulates fatty-acid metabolism in neurodegeneration

661 (Carroll *et al.* 2018) and *BHLHE40* is necessary for insulin-mediated *SREBP1* induction, a lipid homeostasis regulator (Tian *et al.* 2018)

662 lipid homeostasis regulator (Tian *et al.* 2018).

663

Pathway and TF enrichment analysis implicated differential metabolic processes across the 664 665 AD multi-omics datasets, which also exhibited different cell-type enrichments. Cholesterol biosynthesis, phospholipases, fatty-acid metabolism and SREBF1 were strongly enriched in 666 the AD-metabolic transcriptome, which also exhibited astrocyte and microglia cell-type 667 668 enrichment. These multi-level results provide further evidence supporting the existence of wide-spread lipidomic alterations in AD microglia (Wang et al. 2015). Previously, an allele 669 670 variant in the SREPF1 gene was found to be neuroprotective in APOE4 carriers in terms of dementia incidence (Spell et al. 2004). Extensive lipidome changes are present in TREM2-671 defficent microglia, another gene variant heavily implicated in AD pathogenesis (Nugent et 672 al. 2020). Phospholipase-amyloid interactions seem to facilitate microglia AB endocytosis, 673 674 therefore contributing to neuroinflammation (Teng et al. 2019). Aerobic respiration, TCA 675 cycle and glycolysis were enriched in the AD-metabolic proteome; these pathways are consistent with signs of mitochondrial dysfunction that are commonly found in 676 677 neurodegeneration (Wang et al. 2020). Indeed, significant energy metabolism deficits have been detected in human(Johnson et al. 2020) and AD mice brain proteomes (Yu et al. 2018). 678 679

The main finding in this study is the validation of a predicted lipid signature derived from an 680 extracted metabolic subnetwork with all significantly enriched lipid pathways in AD multi-681 omics datasets. The OPLS-DA model for the validated lipid signature in negative ion mode 682 683 LC-MS dataset was capable of driving class separation based on ABCA7 genotype with a higher degree of robustness than in the original dataset; the reduced number of features was 684 not a confounding factor for the model, but instead allowed for the removal of features 685 686 originally decreasing the model robustness. Multi-omics integration is being increasingly 687 used to draw biologically meaningful conclusions over large datasets (Pinu et al. 2019), and has been previously applied to AD data to infer metabolic perturbations using protein 688 ranking and gene-set enrichment (Bundy et al. 2019; Bai et al. 2020), gene-protein 689 690 interaction networks (Canchi et al. 2019) and protein-protein interaction networks (Zhang et al. 2020). To our knowledge, this is the first study using multi-omics pathway-based 691

692 integration and metabolic subnetwork extraction to identify and subsequently validate a lipid 693 metabolic signature in the AD lipidome.

694

695 Eleven lipid species from the validated lipid signature were significantly modulated in the cortical ABCA7 lipidome, of which four belonged to the cholesterol biosynthesis pathway. 696 697 Lathosterol and cholesterol were significantly decreased in the ABCA7-KO lipidome 698 compared to WT, whereas 7-dehydro-cholesterol and  $4\alpha$ -hydroxymethyl-4 $\beta$ -methyl-5 $\alpha$ -699 cholesta-8,24-dien-3β-ol were significantly decreased in ABCA7-females compared to 700 ABCA7-males. The evidence is mixed regarding cholesterol and intermediate sterols changes 701 in ABCA7 mice. One study showed no cholesterol changes in ABCA7-KO mice brains (Satoh et al. 2015); serum cholesterol levels were however decreased in female ABCA7-KO 702 703 mice (Kim et al. 2005). This study appears more aligned with the latter, as decreased free-704 cholesterol levels and sex-specific sterol intermediates differences were detected. This discrepancy is extended to other AD mouse models. Free-cholesterol and lathosterol levels 705 706 exhibited non-significant changes in TgCRND8 (Yang et al. 2014) and APP/PS1 mice (Bogie 707 et al. 2019), whereas lanosterol and cholesteryl acetate were up-regulated in APOE4 mice 708 (Nuriel et al. 2017). Despite these disagreements, the importance of sterol intermediates in 709 AD is reflected therapeutically, as a recent drug-repurposing screen identified several tau-

- reducing compounds which targeted cholesterol-esters (van der Kant et al. 2019). 710
- 711

We also performed an MWAS analysis using SNPs previously associated with LOAD and 712 713 metabolites detected in blood plasma from the Airwave and Rotterdam cohorts using <sup>1</sup>H 714 NMR spectroscopy. Mean ages of recruitment in these cohorts are relatively young, and thus 715 our reported 298 SNP-metabolite associations may represent early stages of the disease, as

- 716 the brain begins to accumulate neurodegenerative features that ultimately results in Mild
- 717 Cognitive Impairment (MCI) and AD. Using three distinct NMR pulse sequences, we were
- able to detect a range of metabolites including lipids, amino acids, glycolysis, TCA cycle 718
- intermediates and ketone bodies. Lipids were the commonest metabolite class represented in 719 720 metabolite-SNP associations, suggesting that dysregulation of lipid metabolism may be some
- 721 of the earliest events in AD.
- 722

There are important limitations associated with this study. Firstly, this study included multi-723 724 omics data from several brain regions, ages and AD mouse models. Therefore, region and

- 725 age-specific TF upstream-regulation and metabolic alterations that are frequent in AD
- 726 (González-Domínguez et al. 2014) were not assessed. It is also notoriously difficult to
- 727 annotate lipid species into GSMNs due to the complexities associated with lipid
- 728 nomenclature and identification (Poupin et al. 2020). This study successfully overcame this
- 729 limitation by allowing second-order lipid species matching to their associated broader lipid
- 730 term whenever unique lipid species matching was not possible (Poupin et al. 2020). This
- 731 study was also limited in that cell type enrichment analysis could not distinguish whether
- 732 astrocytic and microglia enrichment was associated with gliosis in disease rather than AD
- 733 pathology per se, as cell type proportions could not be adequately controlled in silico. Additionally, APOE-associated SNPs dominated our MWAS analysis, which could be 734
- attributed to the known association of ApoE with dyslipidemia and atherosclerosis 735
- 736 (Bouchareychas & Raffai 2018). Furthermore, <sup>1</sup>H NMR spectra of blood plasma detect a high
- proportion of lipids compared with other classes of metabolites and is relatively insensitive as 737
- a technique. We are currently performing mass spectrometry to expand the coverage of the 738
- 739 metabolome to further investigate the earliest molecular events in AD.
- 740
- **5** Conclusions 741

In summary, this study highlights the suitability of integrating multi-omics data into GSMNs to identify metabolic alterations in AD. Pathway-based integration of multi-omics data revealed distinct perturbations in lipid metabolism in the AD mouse brain. Predicted lipids extracted from the over-represented lipid pathway's metabolic subnetwork was validated in the ABCA7 lipidome, with its associated multi-variate model robustly modelling class separation. Furthermore, more than 70% of 298 SNP-metabolite associations in a MWAS corresponded to lipid species, thus validating the presence of lipidomic dysregulation in AD. Author Contributions: M.E.G.S. and J.L.G. conceived and designed the study. M.E.G.S. retrieved and analyzed the transcriptomics, proteomics, GWAS and lipidomics data. B.R.D. acquired the lipidomic data. S.L. and B.R.D. processed the lipidomic data. I.K. performed the MWAS study, which used data from two on-going cohorts oversaw by P.E. M.E.G.S. and J.L.G. interpreted the data. M.E.G.S. drafted the manuscript, which received critical input from J.L.G. All authors have read and approved the published version of the manuscript. **Funding:** This work was supported by the Medical Research Council UK, the UK Dementia Research Institute, National Institute for Health Research (NIHR) and Imperial Biomedical Research Centre. Acknowledgments: The authors would like to acknowledge Dr. Tomonori Aikawa and Professor Takahisa Kanekiyo from the Mayo Clinic, Jacksonville, Florida for providing the 

- 763 ABCA7 cortical mouse tissue.
- **Conflicts of Interest:** The authors declare no conflict of interest.

Supplementary Materials: The following are available: Table S1: Transcription Factor enrichment analysis of all-mapped AD transcriptomics and proteomics datasets; Table S2: Biological Process (BP), Molecular Function (MF) and Cellular Compartment (CC) enrichment analysis of all-mapped AD transcriptomics, proteomics and GWAS-orthologs datasets; Table S3: Transcription Factor enrichment analysis of AD-metabolic transcriptomics and proteomics datasets; Table S4: Metabolic pathway enrichment analysis of AD-metabolic transcriptomics, proteomics and GWAS-orthologs datasets; Table S5: Unconditional and conditional EWCE analysis of AD-metabolic multi-omics datasets. 

792 **References** 793 794 795 Aikawa, T., Holm, M. L. and Kanekiyo, T. (2018) ABCA7 and Pathogenic Pathways of 796 Alzheimer's Disease. Brain Sci 8. Andreas, N. J., Basu Roy, R., Gomez-Romero, M. et al. (2020) Performance of metabonomic 797 798 serum analysis for diagnostics in paediatric tuberculosis. Sci Rep 10, 7302. 799 Auton, A., Brooks, L. D., Durbin, R. M. et al. (2015) A global reference for human genetic 800 variation. *Nature* **526**, 68-74. 801 Aydin, D., Filippov, M. A., Tschäpe, J. A., Gretz, N., Prinz, M., Eils, R., Brors, B. and 802 Müller, U. C. (2011) Comparative transcriptome profiling of amyloid precursor protein family members in the adult cortex. BMC Genomics 12, 160. 803 Bai, B., Wang, X., Li, Y. et al. (2020) Deep Multilayer Brain Proteomics Identifies Molecular 804 805 Networks in Alzheimer's Disease Progression. Neuron 105, 975-991.e977. Bogie, J., Hoeks, C., Schepers, M. et al. (2019) Dietary Sargassum fusiforme improves 806 807 memory and reduces amyloid plaque load in an Alzheimer's disease mouse model. Sci 808 *Rep* 9, 4908. 809 Bouchareychas, L. and Raffai, R. L. (2018) Apolipoprotein E and Atherosclerosis: From 810 Lipoprotein Metabolism to MicroRNA Control of Inflammation. J Cardiovasc Dev 811 *Dis* **5**. 812 Bundy, J. L., Vied, C., Badger, C. and Nowakowski, R. S. (2019) Sex-biased hippocampal 813 pathology in the 5XFAD mouse model of Alzheimer's disease: A multi-omic analysis. 814 J Comp Neurol 527, 462-475. 815 Buniello, A., MacArthur, J. A. L., Cerezo, M. et al. (2019) The NHGRI-EBI GWAS Catalog 816 of published genome-wide association studies, targeted arrays and summary statistics 2019. Nucleic Acids Res 47, D1005-d1012. 817 818 Canchi, S., Raao, B., Masliah, D., Rosenthal, S. B., Sasik, R., Fisch, K. M., De Jager, P. L., Bennett, D. A. and Rissman, R. A. (2019) Integrating Gene and Protein Expression 819 820 Reveals Perturbed Functional Networks in Alzheimer's Disease. Cell Rep 28, 1103-821 1116.e1104. Canzler, S., Schor, J., Busch, W. et al. (2020) Prospects and challenges of multi-omics data 822 integration in toxicology. Arch Toxicol 94, 371-388. 823 824 Carroll, P. A., Freie, B. W., Mathsyaraja, H. and Eisenman, R. N. (2018) The MYC 825 transcription factor network: balancing metabolism, proliferation and oncogenesis. 826 Front Med 12, 412-425. 827 Caspi, R., Billington, R., Ferrer, L. et al. (2016) The MetaCyc database of metabolic pathways and enzymes and the BioCyc collection of pathway/genome databases. 828 829 Nucleic Acids Res 44, D471-480. 830 Castagné R, Boulangé CL, Karaman I et al. (2017) Improving Visualization and 831 Interpretation of Metabolome-Wide Association Studies: An Application in a 832 Population-Based Cohort Using Untargeted (1)H NMR Metabolic Profiling. J 833 Proteome Res 16, 3623-3633. Chadeau-Hyam M, Ebbels TM, Brown IJ et al. (2010) Metabolic profiling and the 834 835 metabolome-wide association study: significance level for biomarker identification. J 836 Proteome Res. 9, :4620-4627. 837 Chazalviel, M., Frainay, C., Poupin, N., Vinson, F., Merlet, B., Gloaguen, Y., Cottret, L. and 838 Jourdan, F. (2018) MetExploreViz: web component for interactive metabolic network 839 visualization. *Bioinformatics* **34,** 312-313. 840 Clough, E. and Barrett, T. (2016) The Gene Expression Omnibus Database. Methods Mol 841 Biol 1418, 93-110.

- Cottret, L., Frainay, C., Chazalviel, M. et al. (2018) MetExplore: collaborative edition and
  exploration of metabolic networks. *Nucleic Acids Res* 46, W495-w502.
- Cutler, R. G., Kelly, J., Storie, K., Pedersen, W. A., Tammara, A., Hatanpaa, K., Troncoso, J.
  C. and Mattson, M. P. (2004) Involvement of oxidative stress-induced abnormalities
  in ceramide and cholesterol metabolism in brain aging and Alzheimer's disease. *Proc Natl Acad Sci U S A* 101, 2070-2075.
- Bavis, C. A., Hitz, B. C., Sloan, C. A. et al. (2018) The Encyclopedia of DNA elements
  (ENCODE): data portal update. *Nucleic Acids Res* 46, D794-d801.
- Bavis, S. and Meltzer, P. S. (2007) GEOquery: a bridge between the Gene Expression
  Omnibus (GEO) and BioConductor. *Bioinformatics* 23, 1846-1847.
- de Leeuw, C. A., Mooij, J. M., Heskes, T. and Posthuma, D. (2015) MAGMA: generalized
  gene-set analysis of GWAS data. *PLoS Comput Biol* 11, e1004219.
- Be Roeck, A., Van Broeckhoven, C. and Sleegers, K. (2019) The role of ABCA7 in
   Alzheimer's disease: evidence from genomics, transcriptomics and methylomics. *Acta Neuropathol* 138, 201-220.
- Bennis, G., Jr., Sherman, B. T., Hosack, D. A., Yang, J., Gao, W., Lane, H. C. and Lempicki,
  R. A. (2003) DAVID: Database for Annotation, Visualization, and Integrated
  Discovery. *Genome Biol* 4, P3.
- B60 DeTure, M. A. and Dickson, D. W. (2019) The neuropathological diagnosis of Alzheimer's
  B61 disease. *Mol Neurodegener* 14, 32.
- Bona A.C., Jiménez B., Schäfer H. et al. (2014) Precision high-throughput proton NMR
  spectroscopy of human urine, serum, and plasma for large-scale metabolic
  phenotyping. *Analytical Chemistry* 86, 9887-9894.
- Elliott, P., Vergnaud, A. C., Singh, D., Neasham, D., Spear, J. and Heard, A. (2014) The
  Airwave Health Monitoring Study of police officers and staff in Great Britain:
  rationale, design and methods. *Environ Res* 134, 280-285.
- Fahy, E., Subramaniam, S., Murphy, R. C. et al. (2009) Update of the LIPID MAPS
  comprehensive classification system for lipids. *J Lipid Res* 50 Suppl, S9-14.
- Faivre, E., Coelho, J. E., Zornbach, K. et al. (2018) Beneficial Effect of a Selective
  Adenosine A(2A) Receptor Antagonist in the APPswe/PS1dE9 Mouse Model of
  Alzheimer's Disease. *Front Mol Neurosci* 11, 235.
- Fang, E. F., Hou, Y., Palikaras, K. et al. (2019) Mitophagy inhibits amyloid-β and tau
  pathology and reverses cognitive deficits in models of Alzheimer's disease. *Nat Neurosci* 22, 401-412.
- Fernandez, C. G., Hamby, M. E., McReynolds, M. L. and Ray, W. J. (2019) The Role of
  APOE4 in Disrupting the Homeostatic Functions of Astrocytes and Microglia in
  Aging and Alzheimer's Disease. *Front Aging Neurosci* 11, 14.
- Frainay, C. and Jourdan, F. (2017) Computational methods to identify metabolic subnetworks based on metabolomic profiles. *Brief Bioinform* 18, 43-56.
- B81 González-Domínguez, R., García-Barrera, T., Vitorica, J. and Gómez-Ariza, J. L. (2014)
   Region-specific metabolic alterations in the brain of the APP/PS1 transgenic mice of
   Alzheimer's disease. *Biochim Biophys Acta* 1842, 2395-2402.
- 884 Griffin, J. L., Liggi, S. and Hall, Z. (2020) CHAPTER 2 Multivariate Statistics in
  885 Lipidomics. In: *Lipidomics: Current and Emerging Techniques*, pp. 25-48. The Royal
  886 Society of Chemistry.
- Hamezah, H. S., Durani, L. W., Yanagisawa, D., Ibrahim, N. F., Aizat, W. M., Makpol, S.,
  Wan Ngah, W. Z., Damanhuri, H. A. and Tooyama, I. (2019) Modulation of
  Proteome Profile in AβPP/PS1 Mice Hippocampus, Medial Prefrontal Cortex, and
  Striatum by Palm Oil Derived Tocotrienol-Rich Fraction. *J Alzheimers Dis* 72, 229246.

- Hamilton, L. K., Dufresne, M., Joppé, S. E. et al. (2015) Aberrant Lipid Metabolism in the
  Forebrain Niche Suppresses Adult Neural Stem Cell Proliferation in an Animal Model
  of Alzheimer's Disease. *Cell Stem Cell* 17, 397-411.
- Hou, Y., Lautrup, S., Cordonnier, S. et al. (2018) NAD(+) supplementation normalizes key
  Alzheimer's features and DNA damage responses in a new AD mouse model with
  introduced DNA repair deficiency. *Proc Natl Acad Sci U S A* 115, E1876-e1885.
- Ikram, M. A., Brusselle, G., Ghanbari, M. et al. (2020) Objectives, design and main findings
  until 2020 from the Rotterdam Study. *Eur J Epidemiol* 35, 483-517.
- Jansen, I. E., Savage, J. E., Watanabe, K. et al. (2019) Genome-wide meta-analysis identifies
   new loci and functional pathways influencing Alzheimer's disease risk. *Nat Genet* 51, 404-413.
- Jiménez, B., Holmes, E., Heude, C. et al. (2018) Quantitative Lipoprotein Subclass and Low
   Molecular Weight Metabolite Analysis in Human Serum and Plasma by (1)H NMR
   Spectroscopy in a Multilaboratory Trial. *Anal Chem* **90**, 11962-11971.
- Johnson, E. C. B., Dammer, E. B., Duong, D. M. et al. (2020) Large-scale proteomic analysis
   of Alzheimer's disease brain and cerebrospinal fluid reveals early changes in energy
   metabolism associated with microglia and astrocyte activation. *Nat Med* 26, 769-780.
- Jones, P., Côté, R. G., Martens, L., Quinn, A. F., Taylor, C. F., Derache, W., Hermjakob, H.
  and Apweiler, R. (2006) PRIDE: a public repository of protein and peptide
  identifications for the proteomics community. *Nucleic Acids Res* 34, D659-663.
- Kassouf, M. T., Hughes, J. R., Taylor, S., McGowan, S. J., Soneji, S., Green, A. L., Vyas, P.
  and Porcher, C. (2010) Genome-wide identification of TAL1's functional targets:
  insights into its mechanisms of action in primary erythroid cells. *Genome Res* 20, 1064-1083.
- Keenan, A. B., Torre, D., Lachmann, A. et al. (2019) ChEA3: transcription factor enrichment
  analysis by orthogonal omics integration. *Nucleic Acids Res* 47, W212-w224.
- Kim, D. K., Han, D., Park, J. et al. (2019) Deep proteome profiling of the hippocampus in the
  5XFAD mouse model reveals biological process alterations and a novel biomarker of
  Alzheimer's disease. *Exp Mol Med* 51, 1-17.
- 921 Kim, W. S., Fitzgerald, M. L., Kang, K. et al. (2005) Abca7 null mice retain normal
  922 macrophage phosphatidylcholine and cholesterol efflux activity despite alterations in
  923 adipose mass and serum cholesterol levels. *J Biol Chem* 280, 3989-3995.
- Kunkle, B. W., Grenier-Boley, B., Sims, R. et al. (2019) Genetic meta-analysis of diagnosed
   Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and
   lipid processing. *Nat Genet* 51, 414-430.
- Lachen-Montes, M., González-Morales, A., Palomino, M. et al. (2019) Early-Onset
   Molecular Derangements in the Olfactory Bulb of Tg2576 Mice: Novel Insights Into
   the Stress-Responsive Olfactory Kinase Dynamics in Alzheimer's Disease. *Front Aging Neurosci* 11, 141.
- Barbert, J. C., Ibrahim-Verbaas, C. A., Harold, D. et al. (2013) Meta-analysis of 74,046
  individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet*45, 1452-1458.
- Liggi, S., Hinz, C., Hall, Z., Santoru, M. L., Poddighe, S., Fjeldsted, J., Atzori, L. and Griffin,
  J. L. (2018) KniMet: a pipeline for the processing of chromatography-mass
  spectrometry metabolomics data. *Metabolomics* 14, 52.
- Liu, K. D., Acharjee, A., Hinz, C. et al. (2020) Consequences of Lipid Remodeling of
   Adipocyte Membranes Being Functionally Distinct from Lipid Storage in Obesity. J
   *Proteome Res* 19, 3919-3935.

- Mancuso, R., Van Den Daele, J., Fattorelli, N. et al. (2019) Stem-cell-derived human
  microglia transplanted in mouse brain to study human disease. *Nat Neurosci* 22, 2111-2116.
- Marioni, R. E., Harris, S. E., Zhang, Q. et al. (2018) GWAS on family history of Alzheimer's disease. *Transl Psychiatry* 8, 99.
- Marsh, S. E., Abud, E. M., Lakatos, A. et al. (2016) The adaptive immune system restrains
  Alzheimer's disease pathogenesis by modulating microglial function. *Proc Natl Acad Sci U S A* 113, E1316-1325.
- 948 Murgia, F., Muroni, A., Puligheddu, M. et al. (2017) Metabolomics As a Tool for the
  949 Characterization of Drug-Resistant Epilepsy. *Front Neurol* 8, 459.
- 950 Nugent, A. A., Lin, K., van Lengerich, B. et al. (2020) TREM2 Regulates Microglial
  951 Cholesterol Metabolism upon Chronic Phagocytic Challenge. *Neuron* 105, 837952 854.e839.
- Nuriel, T., Angulo, S. L., Khan, U. et al. (2017) Neuronal hyperactivity due to loss of
   inhibitory tone in APOE4 mice lacking Alzheimer's disease-like pathology. *Nat Commun* 8, 1464.
- Oberg, A. L. and Mahoney, D. W. (2012) Statistical methods for quantitative mass
   spectrometry proteomic experiments with labeling. *BMC Bioinformatics* 13 Suppl 16,
   S7.
- Palomino-Alonso, M., Lachén-Montes, M., González-Morales, A., Ausín, K., PérezMediavilla, A., Fernández-Irigoyen, J. and Santamaría, E. (2017) Network-Driven
  Proteogenomics Unveils an Aging-Related Imbalance in the Olfactory IκBα-NFκB
  p65 Complex Functionality in Tg2576 Alzheimer's Disease Mouse Model. *Int J Mol Sci* 18.
- Pappireddi, N., Martin, L. and Wühr, M. (2019) A Review on Quantitative Multiplexed
   Proteomics. *Chembiochem* 20, 1210-1224.
- Perez Ortiz, J. M. and Swerdlow, R. H. (2019) Mitochondrial dysfunction in Alzheimer's
  disease: Role in pathogenesis and novel therapeutic opportunities. *Br J Pharmacol*176, 3489-3507.
- Pinu, F. R., Beale, D. J., Paten, A. M., Kouremenos, K., Swarup, S., Schirra, H. J. and
  Wishart, D. (2019) Systems Biology and Multi-Omics Integration: Viewpoints from
  the Metabolomics Research Community. *Metabolites* 9.
- Polito, V. A., Li, H., Martini-Stoica, H. et al. (2014) Selective clearance of aberrant tau
  proteins and rescue of neurotoxicity by transcription factor EB. *EMBO Mol Med* 6, 1142-1160.
- Poupin, N., Vinson, F., Moreau, A. et al. (2020) Improving lipid mapping in Genome Scale
  Metabolic Networks using ontologies. *Metabolomics* 16, 44.
- 977 Preuss, C., Pandey, R., Piazza, E. et al. (2020) A novel systems biology approach to evaluate
  978 mouse models of late-onset Alzheimer's disease. *Mol Neurodegener* 15, 67.
- 879 Robinson, O., Chadeau Hyam, M., Karaman, I. et al. (2020) Determinants of accelerated
  800 metabolomic and epigenetic aging in a UK cohort. *Aging Cell* 19, e13149.
- Satoh, K., Abe-Dohmae, S., Yokoyama, S., St George-Hyslop, P. and Fraser, P. E. (2015)
  ATP-binding cassette transporter A7 (ABCA7) loss of function alters Alzheimer
  amyloid processing. *J Biol Chem* 290, 24152-24165.
- 984 Skene, N. G., Bryois, J., Bakken, T. E. et al. (2018) Genetic identification of brain cell types
   985 underlying schizophrenia. *Nat Genet* 50, 825-833.
- Skene, N. G. and Grant, S. G. (2016) Identification of Vulnerable Cell Types in Major Brain
   Disorders Using Single Cell Transcriptomes and Expression Weighted Cell Type
   Enrichment. *Front Neurosci* 10, 16.

- Spell, C., Kölsch, H., Lütjohann, D. et al. (2004) SREBP-1a polymorphism influences the
   risk of Alzheimer's disease in carriers of the ApoE4 allele. *Dement Geriatr Cogn Disord* 18, 245-249.
- Su, M., Subbaraj, A. K., Fraser, K. et al. (2019) Lipidomics of Brain Tissues in Rats Fed
   Human Milk from Chinese Mothers or Commercial Infant Formula. *Metabolites* 9.
- Tautenhahn, R., Patti, G. J., Rinehart, D. and Siuzdak, G. (2012) XCMS Online: a web-based
   platform to process untargeted metabolomic data. *Anal Chem* 84, 5035-5039.
- Team, R. C. (2020) R: A language and environment for statistical computing. R Foundation
   for Statistical Computing, Vienna, Austria.
- 998 Teng, T., Dong, L., Ridgley, D. M., Ghura, S., Tobin, M. K., Sun, G. Y., LaDu, M. J. and
  999 Lee, J. C. (2019) Cytosolic Phospholipase A(2) Facilitates Oligomeric Amyloid-β
  1000 Peptide Association with Microglia via Regulation of Membrane-Cytoskeleton
  1001 Connectivity. *Mol Neurobiol* 56, 3222-3234.
- Tian, J., Wu, J., Chen, X., Guo, T., Chen, Z. J., Goldstein, J. L. and Brown, M. S. (2018)
  BHLHE40, a third transcription factor required for insulin induction of SREBP-1c
  mRNA in rodent liver. *Elife* 7.
- Tusher, V. G., Tibshirani, R. and Chu, G. (2001) Significance analysis of microarrays applied
  to the ionizing radiation response. *Proc Natl Acad Sci U S A* 98, 5116-5121.
- Tyanova, S., Temu, T., Sinitcyn, P., Carlson, A., Hein, M. Y., Geiger, T., Mann, M. and Cox,
  J. (2016) The Perseus computational platform for comprehensive analysis of
  (prote)omics data. *Nat Methods* 13, 731-740.
- Tzoulaki, I., Castagné, R., Boulangé, C. L. et al. (2019) Serum metabolic signatures of
   coronary and carotid atherosclerosis and subsequent cardiovascular disease. *Eur Heart J* 40, 2883-2896.
- van der Kant, R., Langness, V. F., Herrera, C. M. et al. (2019) Cholesterol Metabolism Is a
   Druggable Axis that Independently Regulates Tau and Amyloid-β in iPSC-Derived
   Alzheimer's Disease Neurons. *Cell Stem Cell* 24, 363-375.e369.
- Wang, E., Zhu, H., Wang, X., Gower, A. C., Wallack, M., Blusztajn, J. K., Kowall, N. and
  Qiu, W. Q. (2017) Amylin Treatment Reduces Neuroinflammation and Ameliorates
  Abnormal Patterns of Gene Expression in the Cerebral Cortex of an Alzheimer's
  Disease Mouse Model. *J Alzheimers Dis* 56, 47-61.
- Wang, W., Zhao, F., Ma, X., Perry, G. and Zhu, X. (2020) Mitochondria dysfunction in the
   pathogenesis of Alzheimer's disease: recent advances. *Mol Neurodegener* 15, 30.
- Wang, Y., Cella, M., Mallinson, K. et al. (2015) TREM2 lipid sensing sustains the microglial
   response in an Alzheimer's disease model. *Cell* 160, 1061-1071.
- Xie, L., Varathan, P., Nho, K., Saykin, A. J., Salama, P. and Yan, J. (2020) Identification of
   functionally connected multi-omic biomarkers for Alzheimer's disease using
   modularity-constrained Lasso. *PLoS One* 15, e0234748.
- Yang, D. S., Stavrides, P., Saito, M. et al. (2014) Defective macroautophagic turnover of
   brain lipids in the TgCRND8 Alzheimer mouse model: prevention by correcting
   lysosomal proteolytic deficits. *Brain* 137, 3300-3318.
- Yu, H., Lin, X., Wang, D. et al. (2018) Mitochondrial Molecular Abnormalities Revealed by
   Proteomic Analysis of Hippocampal Organelles of Mice Triple Transgenic for
   Alzheimer Disease. *Front Mol Neurosci* 11, 74.
- Zeisel, A., Muñoz-Manchado, A. B., Codeluppi, S. et al. (2015) Brain structure. Cell types in
  the mouse cortex and hippocampus revealed by single-cell RNA-seq. *Science* 347,
  1138-1142.
- 1036 Zerbino, D. R., Achuthan, P., Akanni, W. et al. (2018) Ensembl 2018. *Nucleic Acids Res* 46, D754-d761.

- Zhang, X., Liu, W., Cao, Y. and Tan, W. (2020) Hippocampus Proteomics and Brain
   Lipidomics Reveal Network Dysfunction and Lipid Molecular Abnormalities in
   APP/PS1 Mouse Model of Alzheimer's Disease. *J Proteome Res* 19, 3427-3437.
- 1041 Zhou, Q., Liu, M., Xia, X. et al. (2017) A mouse tissue transcription factor atlas. *Nat* 1042 *Commun* 8, 15089.